Slide 1: Immunic Therapeutics: IMU-838 Phase 2 Top-Line Data EMPhASIS Trial in RRMS
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains”forward-looking statements" that in volve substantial risksand uncertainties for purposes of the safe harbor within the meaning of Section 27Aof the Securities Act of 1933, asamended, and Section 21€ ofthe Securities Exc
Slide 3: Development Pipeline
Development Pipeline Program | Indication Target Preclinical Phase 1 Phase 2 Phase 3 Imu-838 Multiple Sclerosis DHODH = Ulcerative Colitis DHODH _——————————— Crohn's Disease DHODH st SS psc DHODH TT coviD-1s* DHODH See imu-935 Psoriasis RORyt OS Orphan Al Diseases RORyt k= £.#§|+#$=«C IMU-856 a Inte
Slide 4: Treatment Compliance and Persistence are Important Considerations for MS
Treatment Compliance and Persistence are Important Considerations for MS Disease Course! Preclinical phase It + Relapsing-remitting phase ft tit t it Clinical disability MRI activity Secondary progressive phase Brain volume asia - i i lx? years >|<— 10-15 years —>|<—— 20 + years —> Life-Long Disease
Slide 5: The Global MS Drug Market was 22 Billion USD in 2016
The Global MS Drug Market was 22 Billion USD in 2016 = Global market of MS drugs was USD 22 billion in 2016") = Currently approved drugs include oral and injectable drugs - Early injectables US$22 : - Interferons (e.g. Rebif®, Avonex®) ayer - Glatiramer acetate - Oral drugs - Teriflunomide - Dimethy
Slide 6: Current Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Current Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) Escalation Treatment Approach in RRMS BaseMedications Escalation Treatments = Currently, there is no specific guidance on which Treatment-naive Patients 2nd/3rd Line Treatments CE actiity ee therapies/medications are used in which se
Slide 7: IMU-838: Target Profile in Relapsing-Remitting Multiple Sclerosis
IMU-838: Target Profile in Relapsing-Remitting Multiple Sclerosis IMU-838 is Intended to be a Selective Once Daily Medication for RRMS Patients With a Well- Balanced Combination of Favorable Safety and Convenience Profile with Robust Clinical Activity For Patient For Neurologist Convenient safety pr
Slide 8: IMU-838 in Relapsing-Remitting Multiple Sclerosis (RRMS)
Slide 9: EMPhASIS: Phase 2 Study Overview in RRMS
EMPhASIS: Phase 2 Study Overview in RRMS Population: RRMS With Sor Relevant Disease Activity = Male or female (182 age <55) P Coordinating Investigator = RRMS diagnosis (Revised McDonald criteria 2017) = Evidence of disease activity based on relapse and MRI criteria = Baseline EDSS: 0 > EDSS < 4.0 R
Slide 10: EMPhASIS: Phase 2 Trial Design in RRMS
EMPhASIS: Phase 2 Trial Design in RRMS 30mgiMU-838 — EoMT ————— 30mgIMU-838 — 300r45 mgIMU-838°— — EoT. 45mgiMU-838 — EoMT ————— 45mgiMU-838 — 30o0r45 mgIMU-838° — _EoT Scr.exam. BL MRI Placebo = — EoMT 30mgiMU-838 — 300r45 mgIMU-838® —__ EoT. 45 mgiMU-838 — 300r45 mgIMU-838° — _EoT l | | | | | | D-
Slide 11: Patient Disposition and Treatment Discontinuations
Patient Disposition and Treatment Discontinuations Yao Randomized Patients N=210 cee a Not Dosed Nel lt Discontinued N=3 Sa Discontinued N=5. a a Completed Week 24 Sea 11 | ©tmmunic, inc. | 08/03/2020 Completed Week 24 N=64 N=68 i See a 45 mg IMU-838, N=69 Discontinued N=4 i Completed Week 24 5 Teer
Slide 12: Primary and Key Secondary Efficacy Endpoints
Primary and Key Secondary Efficacy Endpoints All MRI Scans Were Assessed Centrally by an Independent MRI Reading Center Only Key Study Endpoints To evaluate the efficacy of IMU-838 as compared to placebo based Baseline Blinded Treatment onthe cumulative number of new combined unique active lesions u
Slide 13: Efficacy
Slide 14: Primary and Key Secondary Endpoints Met With High Statistical Significance
EMPhASIS Trial NCT03846219 Primary and Key Secondary Endpoints Met With High Statistical Significance
Slide 15: Study Met Primary and Key Secondary Endpoints
Study Met Primary and Key Secondary Endpoints High Statistical Significance and Robust Results Regarding Suppression of CUA MRI Lesions Suppression of p-value Analysis Set IMU-838 | Placebo CUA MRI Lesions (1-sided) IMU-838 vs. Placebo Pri 45 IMU-838 ered a FullAnalysisSet* | N=69 62% 0.0002 Endpoin
Slide 16: Perspective of IMU-838 Data Versus Other Phase 2 Trials in RRMS
Perspective of IMU-838 Data Versus Other Phase 2 Trials in RRMS IMU-838 Data on Suppression of MRI Activity Compares Favorably to Other First-Line and Oral Medications in RRMS* of MRI Activit IMu-838 IMu-838 @etihemie | eeitmenititse| 2mm Finpoliodala mecinenimod.! acetate!!! fumaratel?) Administrat
Slide 17: Meta-Analysis: Prediction of Relapse Reduction From MRI Activity
Meta-Analysis: Prediction of Relapse Reduction From MRI Activity log(MRleffect) — Data for present analysis — Data froma previous meta-analysis 30 Tog(RELeffect) = Meta-analysis of 54 published trials for the treatment of relapsing-remitting multiple sclerosis") = Allows a robust estimation of the a
Slide 18: Secondary Endpoints: New Gadolinium-Enhancing MRI Lesions
Secondary Endpoints: New Gadolinium-Enhancing MRI Lesions Number of Patients Without Any Gadolinium MRI Lesions Over Entire 24-Week Treatment Period* Cumulative number of new enhancing Gadolinium- enhancing MRI lesions at Week 24* Number of Patients Without Any ae pail Treatment Group Gadolinium MRI
Slide 19: Secondary Endpoints: Relapse-Related Endpoints
Secondary Endpoints: Relapse-Related Endpoints Effect on Annualized Relapse Rate (ARR) Relapse-Free Patients Over Entire 24-Week Treatment Period k Treat mentGrorl Number of Patients Free of Relapse Treatment Adjusted Mean Ba apse P During Entire 24-Week Treatment Period G N ARR Suppression a Versus
Slide 20: Conclusions Regarding Efficacy
Conclusions Regarding Efficacy = Primary and key secondary endpoints met with high statistical significance = All other secondary endpoints, including those based on other MRI parameters and on clinical endpoints such as relapse event, also provided a noticeable signal and numerical benefit for the
Slide 21: Safety
Slide 22: Overall Rate of Patients With Treatment Emergent Adverse Events
Overall Rate of Patients With Treatment Emergent Adverse Events Treatment Group | Number of TEAE eat alle 30 mg IMU-838 | 70 32/71 (45.1%) |45 mg IMU-838 59 28/69 (40.6%) Placebo 62 30/69 (43.5%) There were 3 patientswith serioustreatment-emergent adverse events (SAE) inthis trial: = Placebo: Squamo
Slide 23: Reasons for Treatment Discontinuations due to Adverse Events
Reasons for Treatment Discontinuations due to Adverse Events Treatment Discontinuation Before Week 24 (all dosed patients until end of blinded treatment) Placebo. 72% 5/69 All IMU-838 5.0% 7/140 30 mg IMU-838 42% 3/71 45 mg IMU-838 5.8% 4/69 Reasons for Treatment Discontinuation bate || alu eomg Bef
Slide 24: Perspective of IMU-838 Treatment Discontinuation Rates
Perspective of IMU-838 Treatment Discontinuation Rates Versus Other Phase 2 Trials in RRMS IMU-838 Discontinuation Rate Compares Favorably to Other First-Line and Oral Medications in RRMS* IMU-838 IMU-838 Gitte esinnennictse|| PMCS || stperaitinreTe || “tirerttener acetate!) fumaratel?) Administrati
Slide 25: IMU-838: Second Generation, Highly Selective DHODH Inhibitor
IMU-838: Second Generation, Highly Selective DHODH Inhibitor With Distinct Chemical Structure = Aubagio® hits off targets, e.g. protein kinases EGFR and teriflunomide (Aubagio®) Aurora Al2] leading to off-target toxicities®! ) = Aubagio® has a half-life of about 18 to 19 days in humans!*!, wash-out
Slide 26: Teriflunomide Has a Safety and Tolerability Profile Not Expected From Selective DHODH Inhibition
Teriflunomide Has a Safety and Tolerability Profile Not Expected From Selective DHODH Inhibition — Mean lymphocyte eae) Adverse Event Headache ALT increased Diarrhea Alopecia : {| same we Nausea [a] Aubagio®(terfunamice) Prescribirg Infarmatian US FDA, Medical Reviewfarterifunamide, August 25,2012 [
Slide 27: Previous COMPONENT Trial of Vidofludimus
Previous COMPONENT* Trial of Vidofludimus Incidence of Liver Events!" Liver Event TEAE Vidofludimus 35 mg Placebo By Preferred Term n=122 n=119 Biliary Colic J 0 (0.0%) | 1 (0.8%) Hepatic Pain 0 (0.0%) 1 (0.8%) Hepatic Steatosis 0 (0.0%) 1 (0.8%) Hepatocellular Injury 1 (0.8%) 0 (0.0%) g-Glutamyl Tr
Slide 28: EMPhASIS Trial: Detailed Assessment of Liver Events (1)
EMPhASIS Trial: Detailed Assessment of Liver Events (1): Overall Rate of Liver and Renal Events There Was No Increase in Liver or Renal Events for the Pooled IMU-838 Treatment Arms Versus Placebo During Blinded Treatment Period Treatment Group Rate of Patients With Treatment-Emergent Adverse Events
Slide 29: EMPhASIS Trial: Detailed Assessment of Liver Events (2)
EMPhASIS Trial: Detailed Assessment of Liver Events (2) Liver Enzyme Elevations Very few cases of increases of alanine aminotransferase increases (ALT) or aspartate aminotransferase (AST) above the different thresholds of upper limit of normal (ULN) = Such cases are comparable between IMU-838 treatm
Slide 30: EMPhASIS Trial: Detailed Assessment of Liver Events (3)
Peak BILI (xULN] ot EMPhASIS Trial: Detailed Assessment of Liver Events (3) Hy’s Law Assessment Hy’s Law Assessment Hyperbilirubinemia xu Hy’s Law Range owes o id Bom SO os Treatment group 0 45mg MU-838 © 30mg MU-838 1 Placebo Normal range axULN 0.01 on 1 Peak ALT [xULN] 30 | ©immunic, ine. | as/o3/
Slide 31: Conclusions Regarding Safety
Conclusions Regarding Safety = Consistent with prior data sets in other patient populations, administration of IMU-838 in this trial was observed to be well- tolerated, thereby also providing further evidence of a favorable safety profile of IMU-838 in the RRMS patient population. — In general, safe
Slide 32: Status Quo and Outlook
Status Quo and Outlook Available Top-Line Data Announced Today Analysis of the full EMPhASIS data is ongoing andis intended to be presented at the joint ACTRIMS-ECTRIMS scientific meeting on September 11 to 13, 2020 More detailed safety data (in particular, diarrhea, alopecia, neutropenia) are not y
Slide 33: Summary
Summary Positive Clinical Activity Data Achieved and Unique Safety Properties of IMU-838 Further Support Potential as Best-in-Class Drug Candidate IMU-838 showed compellingclinical activity in this phase 2 trial Unique safety properties compared with current RRMS treatment options We believe it woul
Slide 34: Thank You!
Thank You! Immunic AG Immunic, Inc. Grafelfing near Munich 1200 Avenue of the Americas Germany New York City, NY 10036 USA A <= ___Immunic Research GmbH === A weinberg Campus Hallle (Saale) Germany Immunic Australia Pty. Ltd. ‘Melbourne Australia 34 | ©lmmunic, inc. | as/o3/2020
Slide 35: Immunic, Inc.
Immunic, Inc. 1200 Ave of the Americas, Suite 200 New York, NY 10036, USA i) www.imux.com 35 | ©lmmunic, ine. | as/o3/2020 Head of IR & Communications Phone: +49 89 2080 477 09 Email: ir@imux.com & Immunic